Alex Martin is the Chief Executive Officer of Abcuro, a clinical-stage biotech in Newton, Massachusetts working on selectively depleting highly cytotoxic T cells in autoimmune disease and cancer. A biopharma operator with more than 30 years of company-building and deal-making, he has run Palladio Biosciences and Realm Therapeutics (both acquired), served as COO of Intercept Pharmaceuticals and CFO of BioXell, and held business-development leadership at Novartis. In February 2025 he steered Abcuro to a $200 million Series C led by New Enterprise Associates. He also chairs the board of Veralox Therapeutics, sits on the board of ESSA Pharma, coaches senior executives, and lectures at Wharton and Columbia Business School.
Abcuro is a clinical-stage biotechnology company in Newton, Massachusetts developing first-in-class immunotherapies that selectively deplete highly cytotoxic T cells implicated in autoimmune tissue damage and certain cancers. Its lead program, ulviprubart (ABC008), is a monoclonal antibody targeting the KLRG1 receptor, advanced primarily for inclusion body myositis (IBM) - a progressive muscle-wasting disease with no approved treatments - alongside pipeline work in T-cell large granular lymphocytic leukemia and T/NK-cell lymphomas.